
Revolution Medicines (RVMD): RASONQUE Launch Drives Growth
Revolution Medicines has crossed into commercial oncology with a strong RASONQUE launch, but heavy losses and a rich valuation keep the stock at Hold. The pipeline and clinical data support the long-term story, yet near-term upside looks balanced against execution risk.


